Evidence Vault

The Regulatory Catalyst: Collapsing the Two-Tier SystemThe U.S. biosimilar market, valued at approximately $7.7 billion in 2025, is entering a period of exponential acceleration. While biologics represent a high-margin innovation play, biosimilars are the volume-driven "generic" engine of the 2026 health economy, with a projected CAGR of 18% through 2034.This growth is being triggered by a profound shift in FDA policy under Commissioner Marty Makary. Historically, a biosimilar could only be substituted for a brand-name biologic at the pharmacy if the manufacturer completed expensive "switching studies." These trials required patients to alternate multiple times between the original drug and the biosimilar to prove no loss of efficacy—a process that cost between $100 million and $300 million and added five to eight years to the development timeline.In 2026, the FDA has finalized guidance that removes the requirement for these human switching studies. The agency’s new position is that modern analytical methods are now precise enough to determine equivalence without redundant clinical testing. Consequently, the FDA is moving toward a model where all biosimilars are interchangeable by default, allowing for automatic substitution at the point of sale, just like small-molecule generic pills.The Evidence Gap: The "Trust Gap" in Automatic SubstitutionWhile the regulatory "red tape" has been removed, a significant Evidence Gap remains. Brand-name manufacturers have historically used the lack of an interchangeable designation to sow doubt among physicians and patients regarding the safety of switching. Even as the FDA streamlines the process, the clinical community still demands proof that these drugs perform identically in the "real world".Legacy data systems—reliant on Administrative Proxies (Data Exhaust)—cannot bridge this trust gap. For a biosimilar to capture meaningful market share in a competitive oncology or immunology landscape, the manufacturer and the clinical network must provide Verified Clinical Veracity that goes beyond the lab and into the clinic.The Circle Solution: Engineering the Evidence for VolumeThe Circles platform provides the necessary Regulatory-Grade Governance to dominate the new biosimilar landscape. By using Observational Protocols (OPs), Circles enable clinicians to track the real-world impact of biosimilar substitution with a level of precision that traditional EHR systems cannot match.Audit-Ready "Ground Truth": Circles capture Standardized Longitudinal Scores (e.g., patient-reported outcomes and objective laboratory markers) directly at the clinical node. This provides the permanent, timestamped audit trail needed to prove clinical equivalence to skeptical physicians and payers.Insurable Risk Modeling: By monitoring the "switch" in real-time, Circles provide Insurable Integrity for the medical director and the MSO board. It provides the safety data required to defend against any claims of diminished efficacy, effectively Surgical-Delay Proofing the transition to lower-cost biosimilar protocols.Outcome Engineering: For biosimilar manufacturers, Circles offer a way to bypass the "reproducibility crisis" of the past. They create a Strategic Monopoly on high-veracity outcome data, ensuring their product is the preferred choice for Value-Based Contracting.Strategic Outcome: Valuation via Tech-Enabled ScaleIn the new 2026 biosimilar era, the clinical organization is no longer just a "purchaser" of drugs; it is a producer of Regulatory-Grade Evidence. By adopting Circles, an MSO reclassifies itself from a low-margin "Service Business" into a Tech-Enabled Asset.The value of the enterprise is driven by its ability to prove that its high-volume biosimilar utilization is delivering identical clinical outcomes to the expensive reference biologic. This Multiple Expansion (moving from 6–8x to 12–15x) is the direct result of owning the "Ground Truth" in a market where the FDA has traded pre-market trials for real-world veracity.

The Market Catalyst: The 51% Spend CrisisBy early 2026, biologics have become the primary economic driver of U.S. healthcare. While these complex, large-molecule treatments represent only 5% of all prescriptions, they now account for an staggering 51% of total drug spending as of late 2025. The U.S. biologics market is currently valued at approximately $203.6 billion, with projections indicating it will exceed $483 billion by 2034.Commissioner Marty Makary has identified this concentration of spend as a systemic inefficiency, often referring to the high cost of biologics as a barrier to patient access. In response, the FDA has initiated a pivot toward "Analytical Veracity." For new biologics—particularly monoclonal antibodies (mAbs), which account for nearly 70% of the market share — the agency is beginning to replace multi-year human trials with advanced laboratory characterization and real-time monitoring.The Evidence Gap: The High-Stakes Licensing RiskAs the FDA accelerates the approval of these molecules through the National Priority Voucher and other fast-track programs, the primary risk for manufacturers and clinicians moves from "regulatory approval" to "market sustainability". When a biologic with a six-figure annual price tag is approved on an accelerated timeline, payers — both public and private — demand more than a preliminary snapshot; they demand Verified Clinical Veracity.Legacy healthcare data systems fail this test. Most existing data consists of Administrative Proxies (Data Exhaust) captured for billing, which lacks the clinical depth to prove long-term efficacy or address the "Measurement-to-Management Gap" that stalls value-based transitions. Without Audit-Ready "Ground Truth", high-value biologics face the constant threat of "reimbursement limbo".The Circle Solution: Building the Infrastructure of EvidenceThe Circles platform provides the Regulatory-Grade Governance required to secure these high-valuation assets across any specialty, from oncology to immunology. By defining the data architecture via Observational Protocols (OPs) before the biologic is administered, Circles ensure that every patient encounter generates a high-fidelity dataset.Outcome Engineering: Circles capture Standardized Longitudinal Scores (e.g., functional assessments and metabolic markers) at the point of care, providing the permanent audit trail necessary to justify premium pricing to payers.Insurable Integrity: By providing Verified Clinical Veracity, Circles create a "shield" for the clinical node, making billing errors or protocol deviations technically impossible and ensuring the data is ready for federal scrutiny.Strategic Monopoly: High-volume, high-veracity data sets within a Circle enable the use of Synthetic Control Arms (SCAs), which can supplement or even replace traditional clinical trials, creating a strategic advantage for manufacturers and clinical networks alike.Strategic Outcome: Valuation via Tech-Enabled AssetsIn the legacy model, biologics were a "pass-through" cost for clinics. In the 2026 regulatory environment, the data generated by these treatments is the asset. By utilizing Circles to provide Insurable Integrity, a Management Services Organization (MSO) reclassifies itself as a Tech-Enabled Asset.This shift is the primary driver for Multiple Expansion, moving an organization from a standard 6–8x service multiple to a 12–15x asset multiple. The value is no longer in the administration of the drug, but in the "Ground Truth" evidence that secures its place in the market.

The Regulatory Catalyst: The 2026 Quality Cap and "Safety of Care" MandatesIn 2026, the Centers for Medicare & Medicaid Services (CMS) shifted from rewarding "participation" in quality reporting to enforcing strict performance-based "Quality Caps". Under the new 4-star and 5-star cap system, reimbursement for outpatient procedures is no longer guaranteed by volume or necessity alone; it is gated by a facility’s ability to remain within specific "Safety of Care" measure groups.This transition has been accelerated by the 2026 "Site-Neutral" rollout, which aggressively targets musculoskeletal and surgical specialties. For the healthcare executive, the risk is no longer just a reduction in the fee schedule; it is the "Surgical-Delay" — a state where procedures are stalled or denied because the provider cannot meet the increasingly high threshold of pre-operative and post-operative outcome evidence.The Evidence Gap: The Flaw in "Quality Reporting"The primary obstacle to clinical and financial success in 2026 is the reliance on retrospective "Quality Reporting." Traditional systems capture data weeks or months after a procedure, often relying on administrative staff to extract "Data Exhaust" from unstructured electronic health record (EHR) notes.This creates a "Measurement-to-Management Gap." Retrospective data is inherently defensive; it attempts to justify a past action using incomplete records. In an environment where CMS and private payers are utilizing AI to identify safety and efficacy signals in real-time, these "Administrative Proxies" are insufficient to prevent reimbursement denials or justify surgical necessity.The Circle Solution: Surgical-Delay Proofing via Outcome EngineeringThe Circles platform provides the infrastructure to navigate these mandates through Outcome Engineering. By implementing Regulatory-Grade Governance at the point of care, Circles ensure that the evidence required for reimbursement is generated simultaneously with the clinical encounter.Surgical-Delay Proof: Circles capture Standardized Longitudinal Scores (e.g., functional recovery, patient-reported outcomes, and pain scales) using Observational Protocols (OPs). This creates a real-time, "Surgical-Delay Proof" record that preempts payer inquiries by providing the "Ground Truth" of medical necessity and procedural success.Verified Clinical Veracity: Because data is captured within defined clinical guardrails, the resulting dataset possesses Verified Clinical Veracity. This allows the clinical node to meet the CMS 5-star threshold with absolute certainty, securing the highest possible reimbursement tiers.Insurable Integrity: Circles transform clinical documentation into an asset with Insurable Integrity. For MSOs and surgical centers, this data serves as a permanent audit trail that protects against the "repayment risk" associated with federal audits of high-volume surgical programs.Strategic Outcome: Achieving the Valuation PremiumAs Value-Based Contracting becomes the standard in 2026, the ability to provide Audit-Ready "Ground Truth" is the single greatest driver of enterprise value. Organizations that remain tied to legacy EHR reporting will continue to see their margins eroded by quality caps and administrative friction.In contrast, organizations that utilize Circles to provide Verified Clinical Veracity are reclassified as Tech-Enabled Assets. This shift allows an MSO to move from a 6–8x service multiple to a 12–15x tech-enabled asset multiple. The valuation expansion is driven by the fact that the organization is no longer just a provider of care, but a producer of the high-veracity evidence that the global healthcare market—from CMS to private equity—now demands.

The Regulatory Catalyst: Reclaiming Oversight of the Food SystemIn early 2026, the FDA moved to close a decades-old regulatory gap known as the "Generally Recognized as Safe" (GRAS) loophole. For years, this provision allowed food and supplement manufacturers to bypass formal FDA approval by self-declaring that their chemical additives were safe, often based on internal or proprietary research that was never shared with the public or the agency.Under the current administration, the FDA has fundamentally reversed this "honor system." Commissioner Marty Makary has initiated a comprehensive review of chemical additives, starting with the removal of nine artificial petroleum-based dyes from the U.S. food supply. More importantly, the agency now requires that any substance seeking GRAS status must be backed by transparent, peer-reviewed, and — most critically — real-world performance data. This shift aligns with the new "RealFood.gov" initiative, which prioritizes protein-dense, minimally processed nutrition over the refined carbohydrates that have dominated the American diet for fifty years.The Evidence Gap:Self-Reporting vs. Outcome EngineeringThis regulatory pivot has created an immediate "Evidence Gap" for the food, beverage, and nutraceutical industries. For years, these sectors relied on short-term, "Administrative Proxies" to justify safety. These proxies—often limited to acute toxicity studies in animals — lack the clinical depth required to prove long-term metabolic safety in humans.As the FDA and the newly formed Administration for a Healthy America (AHA) begin to investigate the "root causes" of the chronic disease epidemic, the industry can no longer hide behind self-certified safety claims. To remain on the market, manufacturers must now provide Verified Clinical Veracity regarding how their products impact human inflammatory markers, insulin sensitivity, and the gut microbiome over time.The Circle Solution: The Infrastructure ofNutritional TruthThe Circles platform provides the necessary Regulatory-Grade Governance to bridge this gap. By utilizing Observational Protocols (OPs), Circle enables manufacturers, researchers, and clinicians to track the real-world metabolic impact of nutritional interventions with the same rigor as a pharmaceutical trial.Audit-Ready "Ground Truth": Circles capture Standardized Longitudinal Scores — including blood glucose levels, inflammatory cytokines, and body composition — directly at the point of care. This provides a permanent, timestamped audit trail that satisfies the FDA’s new demand for transparent safety data.Outcome Engineering: By moving beyond "Data Exhaust," Circles allow for the creation of high-veracity datasets that prove the efficacy of "food as medicine." This is critical for companies looking to align with the AHA’s focus on reversing chronic disease.Insurable Integrity: For food and supplement brands, providing data through a Circle creates a "shield" of Insurable Integrity. It demonstrates a commitment to transparency that minimizes the risk of federal enforcement actions or consumer litigation.Strategic Outcome: Valuation via Compliance-as-an-AssetIn the legacy regulatory environment, safety data was a compliance cost. In the 2026 environment, it is a valuation driver. Companies that continue to rely on the "GRAS" loophole will be viewed as high-risk liabilities.In contrast, organizations that utilize Circles to provide Verified Clinical Veracity are reclassified as Tech-Enabled Assets. By owning the "Ground Truth" of their products' safety and efficacy, these entities can achieve Multiple Expansion to 12–15x, as their data becomes a critical component of the national metabolic health infrastructure.

The Regulatory Collapse of the 8-Year BarrierFor over a decade, the development of a biosimilar was a grueling marathon of attrition. A typical biosimilar required six to nine years to move from initial development to FDA approval, with costs ranging from $100 million to $300 million. This "Red Tape" was largely defined by the requirement for large-scale Comparative Efficacy Studies (CES), which alone typically required one to three years and accounted for up to $175 million of the total R&D budget.By early 2026, Commissioner Marty Makary has fundamentally dismantled this barrier. Citing the "Biosimilar Void"—where 118 high-value biologics are set to lose patent protection with only 10% having biosimilars in development—the FDA has moved to "halve the time and money" required for market entry. The agency’s new mandate replaces the default requirement for clinical efficacy trials with a focus on "Analytical Veracity". For many well-understood molecules, the R&D timeline is being compressed from nearly a decade down to a target of roughly 30 months.The Evidence Gap: The Risk of Hyper-Speed DevelopmentThis collapse of the development cycle creates a profound Evidence Gap. While "Analytical Veracity" proves a molecule is structurally similar in the lab, it does not capture the "Ground Truth" of how it performs across diverse patient populations in the real world. As the FDA moves toward a "Generics-Style" pathway for biologics, the industry faces a new category of Insurable Risk.Manufacturers and clinicians operating at this new velocity can no longer rely on Administrative Proxies (Data Exhaust). When a drug is approved in 30 months rather than 8 years, the traditional "wait-and-see" approach to safety and efficacy is a liability. Payers and litigators will scrutinize these products with unprecedented intensity, seeking the Verified Clinical Veracity that legacy data systems simply cannot provide.The Circle Solution: Infrastructure for Continuous VeracityThe Circles platform provides the Regulatory-Grade Governance necessary to survive and thrive in a 30-month R&D environment. By implementing Observational Protocols (OPs) at the clinical node, Circles transform the "Post-Market" phase into a high-veracity, real-time clinical trial.Audit-Ready "Ground Truth": Circles capture Standardized Longitudinal Scores (e.g., functional recovery, immunological markers) at the point of care. This ensures that as these compressed-timeline drugs enter the market, their performance is tracked with an integrity that exceeds traditional clinical trials.Insurable Risk Modeling: For the manufacturer, Circles provide the "Human Ground Truth" necessary to validate the analytical models used for approval. This creates the Insurable Integrity required to defend against litigation and secure preferred formulary placement with payers who are skeptical of truncated review windows.Outcome Engineering: By moving the focus from "Data Exhaust" to Outcome Engineering, Circles enable clinical networks to prove that these lower-cost alternatives are delivering identical clinical value to the $200 billion biologic reference products.The Valuation Mechanic: Multiple Expansion through IntegrityThe compression of the R&D cycle has turned "Veracity" into the most valuable asset in the healthcare stack. Organizations that continue to operate on administrative proxies will be viewed as high-risk cost centers in the new regulatory era.In contrast, an MSO that utilizes Circles to provide Verified Clinical Veracity reclassifies itself as a Tech-Enabled Asset. By owning the "Ground Truth" evidence for a market set to save the U.S. healthcare system $181 billion over the next five years, these entities achieve Multiple Expansion from 6–8x to 12–15x. The valuation is no longer driven by the speed of the service, but by the Insurable Integrity of the evidence it creates.

The Regulatory Catalyst: Defining the "Medical-Grade" LaneOn January 6, 2026, the FDA released its revised "General Wellness Policy for Low-Risk Devices," a document Commissioner Marty Makary framed as the agency "getting out of the way" of consumer innovation. The policy allows wearables and apps that estimate physiological parameters — such as blood pressure, glucose trends, and heart rate variability — to operate without premarket review, provided they avoid specific disease-related claims.However, the guidance introduces a critical "Validation Tension." While wellness products are now permitted to display values that "mimic those used clinically," the FDA explicitly prohibits them from claiming "clinical accuracy," "clinical equivalence," or "medical-grade" status unless they undergo formal regulatory scrutiny. For the digital health industry, this creates a bifurcated market: a low-margin consumer wellness tier and a high-margin, regulated clinical tier.The Evidence Gap: The Limits of Descriptive DataThis regulatory boundary creates a significant "Measurement-to-Management Gap." Most consumer health tools are limited to "descriptive" outputs — tracking patterns or trends without providing a clinical conclusion. As soon as a device prompts a specific clinical action or references a diagnostic threshold (e.g., "abnormal" vs. "normal"), it is reclassified as a medical device subject to full FDA oversight.For companies seeking to enter the lucrative clinical market—where their technology is used by physicians to manage chronic disease or titrate medication — the lack of Verified Clinical Veracity is a terminal barrier. "Data Exhaust" from unvalidated sensors is insufficient to support the medical-grade claims required for physician trust, payer reimbursement, and premium pricing.The Circle Solution: The Infrastructure of Clinical ValidationThe Circles platform provides the bridge for digital health companies to move from "wellness" to "medical-grade" status through Outcome Engineering. By embedding Regulatory-Grade Governance into the data collection process, Circles provide the evidence necessary to satisfy the FDA’s highest standards.Verified Clinical Veracity: Circles capture the "Human Ground Truth" required to validate sensor-based outputs against gold-standard clinical benchmarks. This allows developers to move beyond "descriptive trends" to "evaluative insights" backed by an audit-ready dataset.Human-in-the-Loop Governance: The new guidance emphasizes that Clinical Decision Support (CDS) tools must allow healthcare professionals to "independently review" the basis for recommendations. Circles’ architecture is designed for this transparency, ensuring that the clinician remains the primary decision-maker while the data remains Audit-Ready.Insurable Integrity: For a digital health asset to be "prescribable," it must possess Insurable Integrity. Circles provide the longitudinal tracking of outcomes that proves to payers and providers that a technology is a reliable medical instrument rather than a consumer curiosity.Strategic Outcome: Reclassifying Digital Health AssetsThe 2026 guidance has fundamentally changed the valuation logic for health technology. A wellness tool that remains in the "low-risk" category is valued as a consumer subscription business, subject to high churn and price sensitivity.By utilizing Circles to provide Verified Clinical Veracity, an organization can reclassify its technology as a Tech-Enabled Asset. This transition from "Wellness" to "Medical-Grade" is a primary driver of Multiple Expansion, moving an entity from a consumer-tech multiple to a 12–15x clinical-asset multiple. In the new regulatory era, the value of the platform is defined by the Insurable Integrity of its data, not just the features of its hardware.

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper

White Paper